

## Short communication

## Effect of luminal vasopressin on NaCl transport in the medullary thick ascending limb of the rat

Jay Grider, Jeff Falcone, Eric Kilpatrick, Cobern Ott, Brian Jackson \*

*Department of Physiology, University of Kentucky, College of Medicine, Lexington, KY 40536-0084, USA*

Received 11 April 1996; revised 30 July 1996; accepted 2 August 1996

**Abstract**

The aim of the present study was to determine whether vasopressin affects NaCl reabsorption in the medullary thick ascending limb of the loop of Henle when administered selectively to the luminal membrane. At  $5 \times 10^{-6}$  M and  $10^{-8}$  M, luminal [Arg<sup>8</sup>]vasopressin significantly inhibited Cl<sup>-</sup> transport in the in vitro microperfused rat medullary thick ascending limb by  $46.4 \pm 5.9\%$  ( $P < 0.01$ ) and  $32.4 \pm 2.0\%$  ( $P < 0.05$ ) respectively. The response to  $10^{-8}$  M luminal [Arg<sup>8</sup>]vasopressin was completely blocked by the vasopressin V<sub>1</sub> receptor antagonist [ $\beta$ -mercapto- $\beta$ , $\beta$ -cyclopenta-methylenepropionyl<sup>1</sup>,O-Me-Tyr<sup>2</sup>,Arg<sup>8</sup>]vasopressin ( $10^{-6}$  M), and was mimicked by the vasopressin V<sub>1</sub> receptor agonist [Phe<sup>1</sup>,Ile<sup>5</sup>,Orn<sup>8</sup>]vasopressin ( $10^{-8}$  M;  $\Delta - 35.0 \pm 4.5\%$ ;  $P < 0.05$ ). Luminal administration of the vasopressin V<sub>2</sub> receptor agonist [deamino-Cys<sup>1</sup>,D-Arg<sup>8</sup>]vasopressin ( $5 \times 10^{-6}$  M) had no effect on transport. These data suggest that luminal vasopressin can inhibit NaCl transport in the medullary thick ascending limb of the rat via vasopressin V<sub>1</sub> receptors.

**Keywords:** Loop of Henle; [Arg<sup>8</sup>]Vasopressin; Microperfusion, in vitro; Ion transport

**1. Introduction**

The traditional concept that renal tubular transport is modulated by hormones which act via receptors located exclusively on the basolateral membrane appears to be no longer valid. In the proximal tubule for example, angiotensin II can modulate solute transport via receptors located on the luminal as well as the basolateral membrane (Douglas and Hopfer, 1994). Similarly, vasopressin receptors have also been identified on the luminal membrane of the collecting tubule. In the rabbit cortical collecting tubule, the stimulatory effects of basolateral vasopressin on both osmotic water permeability and on NaCl reabsorption can be antagonized by luminal vasopressin (Ando et al., 1991; Ando and Asano, 1993; Naruse et al., 1995). While these responses may be mediated by luminal vasopressin V<sub>1</sub> receptors (Ando and Asano, 1993), Nonoguchi et al. (1995a) have recently reported that vasopressin V<sub>2</sub> as well as V<sub>1</sub> receptors are present on the luminal membrane of the rat inner medullary collecting duct.

It is well established that vasopressin, acting via basolateral membrane vasopressin V<sub>2</sub> receptors can also stimulate NaCl transport in the thick ascending limb of the loop

of Henle (Culpepper and Andreoli, 1983). Recent studies by Burgess et al. (1994) suggest that luminal vasopressin receptors also exist, since sustained increases in intracellular Ca<sup>2+</sup> could be elicited by luminal exposure to vasopressin in the in vitro microperfused medullary thick ascending limb of the rat. The aim of the present study therefore was to determine whether selective luminal administration of vasopressin can modulate NaCl transport in this nephron segment.

**2. Materials and methods***2.1. Tubular microdissection*

Male Sprague-Dawley rats (35–50 g) were anesthetized with sodium pentobarbital (60 mg/kg). The kidneys were perfused in situ via the abdominal aorta with 10 ml of ice-cold bicarbonate-buffered Hanks balanced salt solution containing (in mM): 140 NaCl; 1.4 CaCl<sub>2</sub>; 0.8 MgSO<sub>4</sub>; 5.4 KCl; 0.44 KH<sub>2</sub>PO<sub>4</sub>; 0.33 Na<sub>2</sub>HPO<sub>4</sub>; 4 NaHCO<sub>3</sub> and 100 mg% D-glucose (pH 7.4). The left kidney was removed, transferred to a Petri dish containing ice-cold Hanks supplemented with 0.1% bovine serum albumin (fraction V) and cut into transverse sections. Medullary thick ascending limb segments (0.5–1.0 mm in length) were microdis-

\* Corresponding author. Tel.: (606) 323-5217; fax: (606) 323-1070.

sected from the inner stripe of the outer medulla under stereomicroscopic observation.

## 2.2. *In vitro* microperfusion

Individual thick ascending limb segments were transferred to a temperature-controlled Lucite bathing chamber attached to the stage of a Nikon Diaphot inverted microscope, and microperfused at 8–15 nl/min with albumin-free Hanks utilizing techniques described previously (Grider et al., 1995). The bathing medium (Hanks + albumin) was continuously bubbled with 95% O<sub>2</sub>:5% CO<sub>2</sub>, maintained at 37°C, and exchanged at a rate of 0.5 ml/min throughout the experiment. Tubules were initially allowed to equilibrate for 10–20 min; the perfusate collected during this time was discarded. The standard experimental paradigm consisted of three 10 min control collections and three 10 min post-treatment collections. Chloride transport was calculated as the difference in chloride concentration between the perfusion fluid and the collected fluid (determined by electrometric titration as previously described) multiplied by the volume flow rate. Tubule length was determined with a calibrated micrometer to allow all transport data to be expressed per mm tubule length.

## 2.3. Intracellular Ca<sup>2+</sup> analysis

Intracellular Ca<sup>2+</sup> was measured in *in vitro* microperfused thick ascending limb segments using a fura-2 based fluorescent video imaging system described previously (Grider et al., 1995). Segments were incubated for 20–30 min at room temperature in Hanks containing 2.5 µM fura-2 acetoxymethyl (AM) ester, and subsequently washed extensively with probe-free Hanks. For each experiment, the 340/380 nm fluorescent images were collected at 5 s intervals on optical disc for 30 s prior to and 300 s after treatment. Following each procedure,  $R_{max}$  and  $R_{min}$  values were obtained using the Ca<sup>2+</sup> ionophore bromo-A23187 and the calcium chelator ethyleneglycol-bis-(β-aminoethyl ether) *N,N'*-tetraacetic acid (EGTA) respectively. These values were subsequently used to determine changes in absolute Ca<sup>2+</sup> concentration for each individual tubule (Grider et al., 1995).

## 2.4. Statistical analysis

Data were analyzed statistically by analysis of variance. Specific differences were obtained using post-hoc analysis by the Newman-Keuls multiple range test. Significance was considered to be  $P < 0.05$ .

## 3. Results

For these studies, the standard experimental paradigm requires a complete exchange of the control luminal per-

fusate for perfusate containing selected agonists/antagonists after three initial 10 min control collections. The first series of experiments confirmed that this exchange procedure per se had no effect on transport (Fig. 1, top panel). As presented in Fig. 1 (middle panel), addition of  $5 \times 10^{-6}$  M [Arg<sup>8</sup>]vasopressin to the luminal perfusion solution caused a significant sustained inhibition of Cl<sup>-</sup> transport in the medullary thick ascending limb ( $\Delta - 46.4 \pm 5.9\%$ ;  $P < 0.01$ ). In contrast, addition of the vasopressin V<sub>2</sub> receptor specific agonist [deamino-Cys<sup>1</sup>,D-Arg<sup>8</sup>]vasopressin ( $5 \times 10^{-6}$  M) to the luminal perfusate had no effect on Cl<sup>-</sup> transport (Fig. 1, bottom panel). Two series of experiments suggested that this vasopressin-dependent inhibition of Cl<sup>-</sup> transport is mediated via luminal vasopressin V<sub>1</sub> receptors. Firstly, the reduction in Cl<sup>-</sup> transport caused by luminal perfusion with  $10^{-8}$  M [Arg<sup>8</sup>]vasopressin ( $\Delta - 32.4 \pm 2.0\%$ ;  $P < 0.05$ ; Fig. 2, top panel) could be abolished by preincubation with the vasopressin V<sub>1</sub> receptor antagonist [ $\beta$ -mercapto- $\beta$ , $\beta$ -cyclopenta-methylenepropionyl<sup>1</sup>,O-Me-Tyr<sup>2</sup>,Arg<sup>8</sup>]vasopressin ( $10^{-6}$  M; Fig. 2, middle panel). Secondly, luminal perfusion with the




Fig. 1. Effect of (i) exchange of luminal perfusate alone (top panel), (ii) luminal [Arg<sup>8</sup>]vasopressin ( $5 \times 10^{-6}$  M; middle panel), and (iii) luminal [deamino-Cys<sup>1</sup>,D-Arg<sup>8</sup>]vasopressin ( $5 \times 10^{-6}$  M; lower panel) on Cl<sup>-</sup> transport in the *in vitro* microperfused medullary thick ascending limb of the rat. Each experiment consisted of three control and three post-treatment 10 min fluid collections. Each data point represents the mean  $\pm$  S.E.M. of at least five separate experiments. \*  $P < 0.05$  or less compared to controls.




Fig. 2. Effect of (i) luminal [Arg<sup>8</sup>]vasopressin (AVP; 10<sup>-8</sup> M; top panel), (ii) luminal [Arg<sup>8</sup>]vasopressin (10<sup>-8</sup> M) in the presence of the vasopressin V<sub>1</sub> receptor antagonist [ $\beta$ -mercapto- $\beta$ , $\beta$ -cyclopenta-methylenepropionyl<sup>1</sup>,O-Me-Tyr<sup>2</sup>,Arg<sup>8</sup>]vasopressin (V1 AN; 10<sup>-6</sup> M; middle panel), and (iii) luminal vasopressin V<sub>1</sub> receptor agonist [Phe<sup>1</sup>,Ile<sup>5</sup>,Orn<sup>8</sup>]vasopressin (V1 AG; 10<sup>-8</sup> M; lower panel), on Cl<sup>-</sup> transport in the medullary thick ascending limb of the rat. Each experiment consisted of three control (CON) and three post-treatment 10 min fluid collections. Data points connected by lines represent the mean of the three control and the three post-treatment Cl<sup>-</sup> transport values. Closed triangles represent the mean  $\pm$  S.E.M. for all control and treatment values. \*  $P < 0.05$  or less compared to corresponding controls.

vasopressin V<sub>1</sub> receptor agonist [Phe<sup>1</sup>,Ile<sup>5</sup>,Orn<sup>8</sup>]vasopressin (10<sup>-8</sup> M) reduced Cl<sup>-</sup> transport to a similar extent to that seen with 10<sup>-8</sup> M [Arg<sup>8</sup>]vasopressin alone ( $\Delta - 35.0 \pm 4.5\%$ ;  $P < 0.05$ ; Fig. 2, bottom panel).

Typically, vasopressin V<sub>1</sub> receptors are coupled to phosphatidylinositol metabolism and the consequent inositol trisphosphate-dependent release of Ca<sup>2+</sup> from intracellular stores (Michell et al., 1979). However, in the present studies, neither luminal nor basolateral administration of [Arg<sup>8</sup>]vasopressin ( $5 \times 10^{-6}$  M) had any effect on intracellular Ca<sup>2+</sup> in the in vitro microperfused thick ascending limb (data not shown). In contrast, as reported previously (Grider et al., 1995), basolateral administration of bradykinin (10<sup>-6</sup> M) consistently increased intracellular Ca<sup>2+</sup> in these tubular preparations.

#### 4. Discussion

It is well established that functionally distinct vasopressin receptors exist on the luminal as well as the basolateral membrane of collecting tubule cells (Ando et al., 1991; Ando and Asano, 1993; Naruse et al., 1995; Nonoguchi et al., 1995a). The present studies substantiate a recent report that the rat medullary thick ascending limb of Henle's loop also contains luminal vasopressin receptors (Burgess et al., 1994), and demonstrate for the first time that selective luminal administration of [Arg<sup>8</sup>]vasopressin causes an inhibition of Cl<sup>-</sup> reabsorption. A series of experiments indicate that this luminal receptor is vasopressin V<sub>1</sub>-like since (i) luminal administration of the vasopressin V<sub>2</sub> receptor specific agonist [deamino-Cys<sup>1</sup>,D-Arg<sup>8</sup>]vasopressin had no effect on Cl<sup>-</sup> transport (Fig. 1, lower panel); (ii) the inhibitory effect of [Arg<sup>8</sup>]vasopressin could be completely blocked by preincubation with the vasopressin V<sub>1</sub> receptor antagonist [ $\beta$ -mercapto- $\beta$ , $\beta$ -cyclopenta-methylenepropionyl<sup>1</sup>,O-Me-Tyr<sup>2</sup>,Arg<sup>8</sup>]vasopressin (Fig. 2, middle panel); and (iii) the vasopressin V<sub>1</sub> receptor agonist [Phe<sup>1</sup>,Ile<sup>5</sup>,Orn<sup>8</sup>]vasopressin decreased Cl<sup>-</sup> transport to a similar extent to that seen with [Arg<sup>8</sup>]vasopressin (Fig. 2, lower panel).

The fura-2 fluorescence data (not shown) however are not fully consistent with this conclusion. Typically, vasopressin V<sub>1</sub> receptors are associated with increases in intracellular Ca<sup>2+</sup>, resulting from enhanced phosphatidylinositol metabolism, and the subsequent generation of inositol trisphosphate (Michell et al., 1979). In the present studies, however, neither luminal nor basolateral [Arg<sup>8</sup>]vasopressin had any effect on intracellular Ca<sup>2+</sup> in the rat thick ascending limb. These data conflict with the recent report from Burgess et al. (1994) who demonstrated that vasopressin, but not a vasopressin V<sub>2</sub> specific agonist, significantly increased cytosolic Ca<sup>2+</sup> in the rat thick ascending limb. However, it should be noted that even these data are not totally consistent with a classic vasopressin V<sub>1</sub> receptor-mediated (inositol trisphosphate-dependent) response. Firstly, vasopressin caused a sustained elevation of Ca<sup>2+</sup> which was preceded by a slow onset phase. Secondly, the vasopressin response could be blocked by eliminating Ca<sup>2+</sup> from the extracellular medium. Interestingly, the molecular analysis of vasopressin V<sub>1</sub> receptor localization is similarly inconsistent. For example, Firsov et al. (1994) reported that mRNA for the vasopressin V<sub>1a</sub> receptor is absent from the rat thick ascending limb, while a preliminary study by Nonoguchi et al. (1995b) has reported that vasopressin V<sub>1a</sub> receptor mRNA is restricted to the medullary thick ascending limb of short-looped nephrons under control conditions, but is also detectable in the thick ascending limb of long-looped nephrons after dehydration.

Further studies will be required to establish the intracellular mechanism of action of luminal vasopressin. Our recent studies have demonstrated that the inhibitory effect

of basolateral bradykinin on  $\text{Cl}^-$  reabsorption in the thick ascending limb is mediated by cytochrome P-450-dependent metabolites of arachidonic acid (Grider et al., submitted for publication). Since early studies by Schwartzman et al. (1985) demonstrated that vasopressin stimulated P-450-arachidonic acid metabolism in rabbit thick ascending limb cells, it is tempting to speculate that these metabolites also mediate the inhibitory effects of vasopressin on  $\text{Cl}^-$  transport. In contrast to vasopressin, bradykinin elicited transient increases in intracellular  $\text{Ca}^{2+}$  in the thick ascending limb, suggesting that an early step in the intracellular signaling cascade involves the activation of a  $\text{Ca}^{2+}$ -dependent phospholipase  $\text{A}_2$  leading to the release of arachidonic acid. Clearly, a similar mechanism cannot be proposed for vasopressin, given the lack of effect of this peptide on intracellular  $\text{Ca}^{2+}$ . However, at least in aortic smooth muscle cells, it has been established that vasopressin-dependent release of arachidonic acid is predominantly mediated by a  $\text{Ca}^{2+}$ -independent phospholipase  $\text{A}_2$  (Lehman et al., 1993).

To this point we have not assessed the effects of simultaneous exposure to basolateral and luminal vasopressin on  $\text{NaCl}$  reabsorption in the thick ascending limb. In our hands, basolateral vasopressin causes a modest but significant increase in  $\text{Cl}^-$  transport ( $\Delta + 34.6 \pm 15.7\%$ ;  $P < 0.05$ ). Consequently, based on the present results and on the antagonistic effects of simultaneous exposure to vasopressin in the collecting tubule (Ando et al., 1991; Ando and Asano, 1993; Naruse et al., 1995; Nonoguchi et al., 1995a), we would anticipate that luminal vasopressin will attenuate or eliminate this stimulatory response to basolateral peptide. Clearly, the physiological significance of this interaction will require further study. The urinary concentration of vasopressin ( $10^{-11}$  to  $10^{-9}$  M) is 10–100 times higher than that of plasma ( $10^{-12}$  to  $10^{-10}$  M; Nonoguchi et al., 1995b). Whether the luminal concentration of vasopressin at the level of the thick ascending limb is high enough to affect solute transport *in vivo* remains to be determined.

In summary, the present studies have demonstrated for the first time that selective luminal administration of vasopressin inhibits  $\text{Cl}^-$  absorption in the *in vitro* microperfused medullary thick ascending limb of the rat. Agonist-antagonist studies suggest that this response is mediated by a vasopressin  $\text{V}_1$ -like receptor that is not coupled to phosphatidylinositol metabolism.

## Acknowledgements

These studies were supported by grants from the American Heart Association, Kentucky Affiliate (B.A.J.), NIH grant HL 53818 (J.C.F.) and NASA EPSCoR WKU 522611 (C.E.O.).

## References

- Ando, Y. and Y. Asano, 1993, Functional evidence for an apical  $\text{V}_1$  receptor in rabbit cortical collecting duct, *Am. J. Physiol.* 264, F467.
- Ando, Y., K. Tabei and Y. Asano, 1991, Luminal vasopressin modulates transport in the rabbit cortical collecting duct, *J. Clin. Invest.* 88, 952.
- Burgess, W.J., R.J. Balment and J.S. Beck, 1994, Effects of luminal vasopressin on intracellular calcium in microperfused rat medullary thick ascending limb, *Renal Physiol. Biochem.* 17, 1.
- Culpepper, R.M. and T.E. Andreoli, 1983, Interactions among prostaglandin  $\text{E}_2$ , antidiuretic hormone, and cyclic adenosine monophosphate in modulating  $\text{Cl}^-$  absorption in single mouse medullary thick ascending limbs of Henle, *J. Clin. Invest.* 71, 1588.
- Douglas, J.G. and U. Hopfer, 1994, Novel aspects of angiotensin receptors and signal transduction in the kidney, *Ann. Rev. Physiol.* 56, 649.
- Firsov, D., B. Mandon, A. Morel, J. Merot, S. Le Maout, A.-C. Bellanger, C. de Rouffignac, J.-M. Elalouf and J.-M. Buhler, 1994, Molecular analysis of vasopressin receptors in the rat nephron. Evidence for alternative splicing of the  $\text{V}_2$  receptor, *Pflügers Arch.* 429, 79.
- Grider, J., J. Falcone, E. Kilpatrick, C. Ott and B. Jackson, 1995, Effect of bradykinin on  $\text{NaCl}$  transport in the medullary thick ascending limb of the rat, *Eur. J. Pharmacol.* 287, 101.
- Lehman, J.J., K.A. Brown, S. Ramanadham, J. Turk and R.W. Gross, 1993, Arachidonic acid release from aortic smooth muscle cells induced by  $[\text{Arg}^8]$  vasopressin is largely mediated by calcium-independent phospholipase  $\text{A}_2$ , *J. Biol. Chem.* 268, 20713.
- Michell, R.H., C.J. Kirk and M.M. Billah, 1979, Hormonal regulation of phosphatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin, *Biochem. Soc. Trans.* 7, 861.
- Naruse, M., R. Yoshitomi, K. Hanoka, M. Imai and K. Kurokawa, 1995, Electrophysiological study of luminal and basolateral vasopressin in rabbit cortical collecting duct, *Am. J. Physiol.* 268, F20.
- Nonoguchi, H., A. Owada, N. Kobayashi, M. Takayama, Y. Terada, J. Koike, K. Ujiie, F. Marumo, T. Sakai and K. Tomita, 1995a, Immunohistochemical localization of  $\text{V}_2$  vasopressin receptor along the nephron and functional role of luminal  $\text{V}_2$  receptor in terminal inner medullary collecting ducts, *J. Clin. Invest.* 96, 1768.
- Nonoguchi, H., Y. Nakamura, T. Inoue, Y. Kohda, S. Arima, M. Nakayama and K. Tomita, 1995b, Functional heterogeneity between short- and long-looped medullary thick ascending limbs (sMAL, lMAL), *J. Am. Soc. Nephrol.* 6, 1058.
- Schwartzman, M., N.R. Ferreri, M.A. Carroll, E. Songu-Mize and J.C. McGiff, 1985, Renal cytochrome P-450-related arachidonic acid metabolite inhibits (Na/K) ATPase, *Nature* 314, 620.